PDF(Pubmed)
Abstract：
Parotid gland pathology represents a web of differential diagnoses. There are many complex cases that require extensive diagnostic tests for a complete and correct final pathology diagnosis. Currently the official classification of parotid gland tumors extends over more than 40 subtypes. We performed a query of the PubMed database regarding the use of molecular biology tests in performing a better characterization of the tumors in specific cases. By using fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR) or next-generation sequencing, the team managing complex cases can offer a personalized therapeutic solution. We review the molecular differential diagnosis according to published articles in the last 5 years for many types of parotid gland tumors ranging from benign to borderline malign tumors to malign aggressive tumors. Mucoepidermoid carcinoma is a distinct subtype of parotid malignancy that was the subject of a consistent number of articles. However, the molecular biology diagnosis techniques helped more in excluding the diagnosis of mucoepidermoid carcinoma, and probably retrospectively limiting the number of cases with this final diagnosis. In Romania, the molecular biology diagnosis is available only in limited research facilities and should receive more consistent funding that will make it available on a larger scale. The novelty of this scoping review is that we propose an algorithm for molecular differential diagnosis of the tumors that could be encountered in the parotid gland.
摘要：
腮腺病理学代表了鉴别诊断的网络。有许多复杂的病例需要广泛的诊断测试才能进行完整和正确的最终病理诊断。目前，腮腺肿瘤的官方分类范围超过40种亚型。我们对PubMed数据库进行了查询，以了解分子生物学测试在特定情况下对肿瘤进行更好的表征。通过使用荧光原位杂交（FISH），逆转录聚合酶链反应（RT-PCR）或下一代测序，管理复杂病例的团队可以提供个性化的治疗解决方案。我们根据过去5年发表的文章对许多类型的腮腺肿瘤进行了分子鉴别诊断，从良性到交界性恶性肿瘤到恶性侵袭性肿瘤。粘液表皮样癌是腮腺恶性肿瘤的一种独特亚型，是许多文章的主题。然而,分子生物学诊断技术更有助于排除粘液表皮样癌的诊断，并可能回顾性地限制了最终诊断的病例数。在罗马尼亚,分子生物学诊断仅在有限的研究设施中可用，并且应该获得更一致的资金，这将使其在更大范围内可用。这项范围审查的新颖之处在于，我们提出了一种用于腮腺中可能遇到的肿瘤的分子鉴别诊断的算法。
